The most relevant presentations from 18° edition of SOLACI Sessions, 6th region Pacific, held on 4 and 5 October 2012 in Ecuador.
Vascular complications after valvular replacement using catheter: PARTNER trial findings
Reference: Généreux, et al, for the PARTNER Trial Investigators. JACC 2012; 60 (12):1043-62 Original title: Vascular complications after Transcatheter Aortic Valve Replacement: Insights From the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial The purpose of the study was to investigate the incidence, predictors and vascular complications impact after catheter aortic valve implantation (TAVI) in the PARTNER...
The impact of permanent pacemaker implantation in patients undergoing percutaneous aortic valve replacement.
Reference: Buellesfeld y colaboradores (JACC in press). Percutaneous aortic valve replacement (AVR) is an innovative technique for the treatment of severe aortic stenosis (SAS); this technique has been incorporated with great enthusiasm in clinical practice, particularly for patients with excessive surgical risks. Due to the proximity of the aortic valve, AV node and His bundle, there...
Renal Denervation: a strategy that has come to stay?
Our editors talked with Dr. Marco Wainstein, an active member of SOLACI Web Editorial Board SOLACI WEB: Which is the rationale for renal denervation? Marco Wainstein, MD: The rationale for renal denervation is based on the modification of the sympathetic innervation of the renal arteries affecting both afferent and efferent nerves. Ultimately, renal denervation would...
Drug-Eluting Stents: device without polymers overcomes limitations of first generations stents
The NEXT randomized trial showed the superiority of a polymer-free amphilimus-eluting stent compared to paclitaxel-eluting stents with permanent polymers The NEXT clinical trial (International Randomized Comparison Between DES Limus Carbostent and Taxus Drug-Eluting Stents in the Treatment of De Novo Coronary Lesions), is a multicenter randomized trial (n=296) comparing coronary amphilimus eluting stent Cre8 (CID,...
Hyperglycemia on admission, an excess risk for infarction
Reference: Planer et al. International Journal of Cardiology 2012 (in press) Prognosis of patients enrolled in acute myocardial infarction with ST segment elevation (STEMI) has improved markedly, particularly as a result of reperfusion therapy. Despite these improvements, patients with diabetes mellitus (DM) are a high risk group in the short and long term compared with...
Renal failure in acute myocardial infarction
Reference: Fox y colaboradores. Short-term Outcomes of Acute Myocardial Infarction in Patients with Acute Kidney Injury: A Report from the National Cardiovascular Data Registry. Circulation 2012 (in press). The presence of chronic renal failure is common in patients referred for angioplasty. Its presence is associated with increased mortality and bleeding. However, the prevalence is unknown as...
Six Months Sufficient for Dual Antiplatelet Therapy
Reference: Kandzari DE, Barrer CS, Leon MB, et al. Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. JACC Cardiovasc Interv 2011; 4: 1119-28.2011; 4: 1119-28. Patients treated with zotarolimus-eluting stents (ZES) suffer no excess late ischemic events if they take dual antiplatelet therapy for 6 months instead of 12 months or longer,...
Off-Pump CABG Reduces Postoperative Stroke vs. Standard Surgery
Reference: Afilalo J, RAsti M, Ohayon SM, et al. Off-pump vs on-pump coronary artery bypass surgery: an updated meta-analysis and meta-reggresion of randomized trials. Eur Heart J 2011. Epub ahead of print. Patients who undergo off-pump coronary artery bypass grafting (CABG) surgery experience nearly one-third fewer postoperative strokes than those who receive standard surgery using cardiopulmonary...
Ticagrelor vs. Clopidogrel in ST elevation MI: Pros and cons
Platelet Inhibition in the PLATO study: insights from the ECG substudy. En el Estudio PLATO quedó evidenciado que el Ticagrelor disminuyó la mortalidad a 12 meses en comparación con el Clopidogrel en el tratamiento de pacientes post-angioplastía por un síndrome coronario agudo o por un cuadro estable (4,5 vs. 5,9%; P<0.001). Estos resultados fueron del...